Cyllene Therapeutics, formerly known as EG 427, is a French biotech company focused on developing gene therapies for neurological diseases, particularly targeting bladder dysfunction in patients with spinal cord injuries
Cyllene Therapeutics, formerly known as EG 427, is a French biotech company focused on developing gene therapies for neurological diseases, particularly targeting bladder dysfunction in patients with spinal cord injuries.